In recent times, the role of Rho GTPase Activating Protein17 (ARHGAP17) as a tumor suppressor and negative regulator for Cdc42 and Rac1 has been the subject of investigation by researchers (Guo et al. 2019; Pan et al. 2018). Here, CDC42 is linked to neoplasm.